Reuters logo
BRIEF-Innate Pharma reports IPH4102 final results of the dose-escalation part of the phase I study
October 16, 2017 / 5:11 AM / a month ago

BRIEF-Innate Pharma reports IPH4102 final results of the dose-escalation part of the phase I study

Oct 16 (Reuters) - INNATE PHARMA SA

* IPH4102: FINAL RESULTS OF THE DOSE-ESCALATION PART OF THE PHASE I STUDY

* ‍EXPANSION COHORTS STARTED, INCLUDING 2 COHORTS OF 15 PATIENTS EACH IN TWO CTCL SUBTYPES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below